| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Shanghai Innostar Biotechnology Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥24.67 |
| 52 Week High | CN¥32.00 |
| 52 Week Low | CN¥22.52 |
| Beta | 0 |
| 11 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -8.60% |
Recent News & Updates
Recent updates
Shareholder Returns
| 688710 | CN Life Sciences | CN Market | |
|---|---|---|---|
| 7D | 5.7% | 6.0% | 6.7% |
| 1Y | n/a | -43.6% | -15.5% |
Return vs Industry: Insufficient data to determine how 688710 performed against the CN Life Sciences industry.
Return vs Market: Insufficient data to determine how 688710 performed against the CN Market.
Price Volatility
| 688710 volatility | |
|---|---|
| 688710 Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 6.0% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in CN Market | 8.4% |
| 10% least volatile stocks in CN Market | 3.7% |
Stable Share Price: 688710 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 688710's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1973 | 1,075 | n/a | www.innostar.cn |
Shanghai Innostar Biotechnology Co., Ltd. provides services for drug research and development in China and internationally. The company offers drug discovery, pharmacodynamic study, non-clinical pharmacokinetic evaluation, non-clinical safety evaluation, bioanalysis, and regulatory submission and consultation services. It serves pharmaceutical companies, new drug research and development institutions, and scientific research institutes The company was founded in 1973 and is based in Shanghai, China.
Shanghai Innostar Biotechnology Co., Ltd. Fundamentals Summary
| 688710 fundamental statistics | |
|---|---|
| Market cap | CN¥3.48b |
| Earnings (TTM) | CN¥176.16m |
| Revenue (TTM) | CN¥1.12b |
19.7x
P/E Ratio3.1x
P/S RatioIs 688710 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 688710 income statement (TTM) | |
|---|---|
| Revenue | CN¥1.12b |
| Cost of Revenue | CN¥613.77m |
| Gross Profit | CN¥503.69m |
| Other Expenses | CN¥327.53m |
| Earnings | CN¥176.16m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.25 |
| Gross Margin | 45.07% |
| Net Profit Margin | 15.76% |
| Debt/Equity Ratio | 15.0% |
How did 688710 perform over the long term?
See historical performance and comparison